I'm LongbridgeAI, I can summarize articles.Abcellera Biologics (ABCL) fell 4.72% this week to $10.89, underperforming the S&P 500 by about 3.92 percentage points. The stock had a wide 11.69% trading range. It opened Tuesday at $11.29 and pushed up to $11.64 before fading, hit a Thursday low of $10.32, then stabilised at $10.89 on Friday. The price action was a sharp rise followed by a pullback, with no major company-specific catalyst.
The Week
Abcellera Biologics (ABCL) fell 4.72% this week to $10.89, underperforming the S&P 500 by about 3.92 percentage points. The stock had a wide 11.69% trading range. It opened Tuesday at $11.29 and pushed up to $11.64 before fading, hit a Thursday low of $10.32, then stabilised at $10.89 on Friday. The price action was a sharp rise followed by a pullback, with no major company-specific catalyst.
Analyst Ratings
Out of 9 brokers covering the stock, 8 rate it buy and 1 rates it outperform, with no hold or sell ratings. The consensus rating is strong buy, with a consensus target of $17.125, about 57.25% above the current price. Target prices range from $9.00 to $30.00, showing wide dispersion. ABCL ranks 24th among 54 companies in the life science tools and services industry.
The Week Ahead
Next week brings a busy macro calendar. Tuesday features the New York Fed manufacturing index, with a prior reading of 20.6 and a forecast of 14.75. Wednesday brings retail sales, retail sales ex-autos, import prices, the NAHB housing market index, and EIA crude inventories. There are no major company-specific events scheduled.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.